CH646874A5 - Naehrloesung. - Google Patents
Naehrloesung. Download PDFInfo
- Publication number
- CH646874A5 CH646874A5 CH160081A CH160081A CH646874A5 CH 646874 A5 CH646874 A5 CH 646874A5 CH 160081 A CH160081 A CH 160081A CH 160081 A CH160081 A CH 160081A CH 646874 A5 CH646874 A5 CH 646874A5
- Authority
- CH
- Switzerland
- Prior art keywords
- glycine
- nutrient solution
- oligopeptides
- solution according
- amino acids
- Prior art date
Links
- 235000016709 nutrition Nutrition 0.000 title description 2
- 108010038807 Oligopeptides Proteins 0.000 claims description 46
- 102000015636 Oligopeptides Human genes 0.000 claims description 46
- 239000000243 solution Substances 0.000 claims description 35
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 26
- 235000015097 nutrients Nutrition 0.000 claims description 17
- 108010016626 Dipeptides Proteins 0.000 claims description 16
- 239000004471 Glycine Substances 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 235000020776 essential amino acid Nutrition 0.000 claims description 10
- 239000003797 essential amino acid Substances 0.000 claims description 10
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 10
- 229920005862 polyol Polymers 0.000 claims description 9
- 150000003077 polyols Chemical class 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 7
- 125000000539 amino acid group Chemical group 0.000 claims description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 4
- 239000003925 fat Substances 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- 235000010755 mineral Nutrition 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 239000011573 trace mineral Substances 0.000 claims description 4
- 235000013619 trace mineral Nutrition 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- DQSIXGDDUJJEQH-QRPNPIFTSA-N 2-aminoacetic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound NCC(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 DQSIXGDDUJJEQH-QRPNPIFTSA-N 0.000 claims description 3
- YWEKFRWGKMPCEU-MDTVQASCSA-N 2-aminoacetic acid;(2s)-2-amino-4-methylpentanoic acid Chemical compound NCC(O)=O.CC(C)C[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O YWEKFRWGKMPCEU-MDTVQASCSA-N 0.000 claims description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
- 229920001542 oligosaccharide Polymers 0.000 claims description 3
- 150000002482 oligosaccharides Chemical class 0.000 claims description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 3
- BKKWZCSSYWYNDS-JEDNCBNOSA-N 2-aminoacetic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCC(O)=O.NCCCC[C@H](N)C(O)=O BKKWZCSSYWYNDS-JEDNCBNOSA-N 0.000 claims description 2
- QGTPORGEFWYTOC-MDTVQASCSA-N 2-aminoacetic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCC(O)=O.NCCCC[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O QGTPORGEFWYTOC-MDTVQASCSA-N 0.000 claims description 2
- HQEQLJHXFBKKEN-SCGRZTRASA-N 2-aminoacetic acid;(2s)-2-amino-3-methylbutanoic acid Chemical compound NCC(O)=O.CC(C)[C@H](N)C(O)=O.CC(C)[C@H](N)C(O)=O HQEQLJHXFBKKEN-SCGRZTRASA-N 0.000 claims description 2
- FSSVRLXFJPQUTM-WCCKRBBISA-N 2-aminoacetic acid;(2s)-2-amino-4-methylsulfanylbutanoic acid Chemical compound NCC(O)=O.CSCC[C@H](N)C(O)=O FSSVRLXFJPQUTM-WCCKRBBISA-N 0.000 claims description 2
- IDFKSUXUURJYNF-SCGRZTRASA-N 2-aminoacetic acid;(2s)-2-amino-4-methylsulfanylbutanoic acid Chemical compound NCC(O)=O.CSCC[C@H](N)C(O)=O.CSCC[C@H](N)C(O)=O IDFKSUXUURJYNF-SCGRZTRASA-N 0.000 claims description 2
- FZEBFTHYHFLHGE-WFGSYIHQSA-N 2-aminoacetic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound NCC(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O FZEBFTHYHFLHGE-WFGSYIHQSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 239000008151 electrolyte solution Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- DGRZRONVAUBBJY-NAWJVIAPSA-N 2-aminoacetic acid;(2s)-2-amino-3-(1h-indol-3-yl)propanoic acid Chemical compound NCC(O)=O.C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1.C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 DGRZRONVAUBBJY-NAWJVIAPSA-N 0.000 claims 1
- NYOGGQBMEGUVIX-WCCKRBBISA-N 2-aminoacetic acid;(2s)-2-amino-3-methylbutanoic acid Chemical compound NCC(O)=O.CC(C)[C@H](N)C(O)=O NYOGGQBMEGUVIX-WCCKRBBISA-N 0.000 claims 1
- AYORUWNJMKYNAD-JEDNCBNOSA-N 2-aminoacetic acid;(2s)-2-amino-4-methylpentanoic acid Chemical compound NCC(O)=O.CC(C)C[C@H](N)C(O)=O AYORUWNJMKYNAD-JEDNCBNOSA-N 0.000 claims 1
- UQFMAFYDEDQTCV-PZXRSRGQSA-N 2-aminoacetic acid;(2s,3r)-2-amino-3-hydroxybutanoic acid Chemical compound NCC(O)=O.C[C@@H](O)[C@H](N)C(O)=O.C[C@@H](O)[C@H](N)C(O)=O UQFMAFYDEDQTCV-PZXRSRGQSA-N 0.000 claims 1
- XGKCWNGHLZXLTK-MUWMCQJSSA-N 2-aminoacetic acid;(2s,3r)-2-amino-3-hydroxybutanoic acid Chemical compound NCC(O)=O.C[C@@H](O)[C@H](N)C(O)=O XGKCWNGHLZXLTK-MUWMCQJSSA-N 0.000 claims 1
- MNQVNFIVCSQNGY-FHAQVOQBSA-N 2-aminoacetic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound NCC(O)=O.CC[C@H](C)[C@H](N)C(O)=O MNQVNFIVCSQNGY-FHAQVOQBSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 description 26
- 229940024606 amino acid Drugs 0.000 description 26
- 150000001413 amino acids Chemical class 0.000 description 23
- 239000000203 mixture Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 5
- 239000004473 Threonine Substances 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- -1 met amino acids Chemical class 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 235000014304 histidine Nutrition 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 229960004799 tryptophan Drugs 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 239000000819 hypertonic solution Substances 0.000 description 2
- 229940021223 hypertonic solution Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000003182 parenteral nutrition solution Substances 0.000 description 2
- 235000013930 proline Nutrition 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N 1-(2-azaniumylacetyl)pyrrolidine-2-carboxylate Chemical compound NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- CQBYLZOLQTWVOB-QXGOIDDHSA-N 2-aminoacetic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound NCC(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=CC=C1 CQBYLZOLQTWVOB-QXGOIDDHSA-N 0.000 description 1
- ZEEYNQNRMIBLMK-DFWYDOINSA-N 2-aminoacetic acid;(2s)-2-aminopentanedioic acid Chemical compound NCC(O)=O.OC(=O)[C@@H](N)CCC(O)=O ZEEYNQNRMIBLMK-DFWYDOINSA-N 0.000 description 1
- DEFJQIDDEAULHB-UHFFFAOYSA-N Alanyl-alanine Chemical compound CC(N)C(=O)NC(C)C(O)=O DEFJQIDDEAULHB-UHFFFAOYSA-N 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 108010082406 peptide permease Proteins 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 108010045269 tryptophyltryptophan Proteins 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13030980A | 1980-03-14 | 1980-03-14 | |
| US06/227,127 US4340592A (en) | 1980-03-14 | 1981-01-26 | Nutrient compositions and method of administering the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH646874A5 true CH646874A5 (de) | 1984-12-28 |
Family
ID=26828352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH160081A CH646874A5 (de) | 1980-03-14 | 1981-03-09 | Naehrloesung. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US4340592A (enExample) |
| AT (1) | AT372281B (enExample) |
| AU (1) | AU543401B2 (enExample) |
| CH (1) | CH646874A5 (enExample) |
| DE (1) | DE3108079C2 (enExample) |
| FR (1) | FR2477843A1 (enExample) |
| GB (1) | GB2071670B (enExample) |
| NL (1) | NL190951C (enExample) |
| SE (1) | SE454746B (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3206784C2 (de) * | 1982-02-25 | 1985-05-09 | Pfrimmer & Co Pharmazeutische Werke Erlangen Gmbh, 8520 Erlangen | Glutaminhaltige Zubereitungen für orale oder intravenöse Applikation |
| WO1985003872A1 (en) * | 1984-03-01 | 1985-09-12 | Vernon Erk | Method of lowering blood sugar level in vertebrates |
| DE3586781T2 (de) * | 1984-03-01 | 1993-05-27 | Vernon Erk | Behandlungsverfahren gegen hohen blutdruck bei wirbeltieren. |
| JPS61501561A (ja) * | 1984-03-01 | 1986-07-31 | ア−ク，バ−ノン | 脊椎動物における低血糖症を治療する方法 |
| EP0174957A4 (en) * | 1984-03-01 | 1987-11-09 | Vernon Erk | METHOD FOR THE TREATMENT OF MEMORY DISORDERS IN ELDERLY PEOPLE. |
| EP0182356B2 (en) * | 1984-11-19 | 1998-08-05 | The Montefiore Hospital Association of Western Pennsylvania | Nutrient compositions |
| US5034377A (en) * | 1984-11-19 | 1991-07-23 | Montefiore Hospital Association Of Western Pennsylvania | Aqueous nutrient compositions comprising oligopeptides |
| JPS62149619A (ja) * | 1985-09-05 | 1987-07-03 | Teijin Ltd | 活性型ビタミンｄ３類注射用組成物 |
| DE3601398A1 (de) * | 1986-01-18 | 1987-07-23 | Fresenius Ag | Verwendung von oligopeptiden zur behandlung von cerebralen stoerungen |
| EP0347890B1 (en) * | 1988-06-22 | 1993-03-17 | Roussel Morishita Co., Ltd. | Amino acid nutrient compositions |
| DE68910126T2 (de) * | 1989-03-28 | 1994-03-31 | Kyowa Hakko Kogyo Kk | Nahrungsmittelzusammensetzung. |
| US5576351A (en) * | 1989-12-29 | 1996-11-19 | Mcgaw, Inc. | Use of arginine as an immunostimulator |
| US5189016A (en) * | 1990-05-18 | 1993-02-23 | Clintec Nutrition Co. | Nutrient compositions containing peptides and method for administering the same |
| US5122515A (en) * | 1990-06-19 | 1992-06-16 | Smith Ross C | Nutrient composition containing dipeptides and method for administering the same |
| DE4022267C2 (de) * | 1990-07-12 | 1994-09-15 | Degussa | N-Acyldipeptide und deren Verwendung |
| US5167957A (en) * | 1990-09-06 | 1992-12-01 | Virginia Tech Intellectual Properties, Inc. | Compositions and methods for the treatment of dietary deficiencies |
| US5326569A (en) * | 1992-12-23 | 1994-07-05 | Abbott Laboratories | Medical foods for the nutritional support of child/adult metabolic diseases |
| ES2173109T3 (es) * | 1992-12-23 | 2002-10-16 | Abbott Lab | Alimentos de unso medico destinados parael sostenimiento nutricional de recien nacidos/de bebes que padecen enfermedades metabolicas. |
| JPH06227974A (ja) * | 1993-01-29 | 1994-08-16 | Kyowa Hakko Kogyo Co Ltd | 栄養組成物 |
| US5891459A (en) * | 1993-06-11 | 1999-04-06 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
| US5378722A (en) * | 1993-12-03 | 1995-01-03 | Clintec Nutrition Co. | Nutritional compositions for management of nitrogen metabolism |
| US7371415B1 (en) | 1998-04-03 | 2008-05-13 | The Daily Wellness Company | Method and composition for improving sexual fitness |
| WO1999051252A1 (en) | 1998-04-03 | 1999-10-14 | The Daily Wellness Company | Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation |
| US20050196470A9 (en) * | 1998-04-03 | 2005-09-08 | Wuh Hank C | Method and composition for enhancing sexual desire |
| JP2003501393A (ja) * | 1999-06-05 | 2003-01-14 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ | 心臓血管細胞増殖を阻害するための方法および組成物 |
| US7855181B2 (en) * | 1999-08-13 | 2010-12-21 | University Of Florida Research Foundation, Inc. | Dipeptides for prevention of muscle breakdown and microbial infection |
| US6989164B2 (en) | 2000-12-22 | 2006-01-24 | The Daily Wellness Company | Method and composition for improving male fertility health |
| US6497885B2 (en) * | 2000-12-22 | 2002-12-24 | The Daily Wellness Company | Method and composition for improving fertility health in female and male animals and humans |
| WO2003063891A1 (en) * | 2002-01-29 | 2003-08-07 | Wyeth | Compositions and methods for modulating connexin hemichannels |
| CA2538680A1 (en) * | 2003-09-26 | 2005-04-07 | Bristol-Myers Squibb Company | Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation |
| US20060229256A1 (en) * | 2003-09-26 | 2006-10-12 | Bristol-Myers Squibb Company | Enternal administration of arginine and glutamine for abnormal vascular proliferation |
| EP1737482A4 (en) * | 2004-03-01 | 2010-09-15 | Lumen Therapeutics Llc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES |
| US7846902B2 (en) * | 2005-09-20 | 2010-12-07 | Kyowa Hakko Bio Co., Ltd. | Dipeptide-comprising composition for oral administration |
| EP1957066A4 (en) | 2005-11-11 | 2013-08-28 | V Ravi Chandran | ACETYLATED AMINO ACIDS AS A THROMBOZYTE AGGREGATION INHIBITOR, FOOD AND VITAMIN SUPPLEMENT |
| US8343531B2 (en) * | 2006-04-21 | 2013-01-01 | Meiji Co., Ltd. | Composition containing peptide as active ingredient |
| JP4964957B2 (ja) * | 2006-09-12 | 2012-07-04 | エフ．ホフマン−ラ ロシュ アーゲー | 抗薬物抗体アッセイ |
| US8257938B2 (en) * | 2009-02-27 | 2012-09-04 | Medical Diagnostic Laboratories, Llc | Hemolysin and its protein fragments in sero-detection of Anaplasma phagocytophilum |
| CN107744140A (zh) * | 2017-11-06 | 2018-03-02 | 威海红印食品科技有限公司 | 一种预消化型全营养液及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH591918A5 (enExample) * | 1974-03-05 | 1977-10-14 | Nestle Sa | |
| CH594367A5 (enExample) * | 1974-05-17 | 1978-01-13 | Brenner Beat Max | |
| US4024286A (en) * | 1976-05-17 | 1977-05-17 | Miles Laboratories, Inc. | Fortification of foodstuffs with C-terminal amino acid substituted methionine dipeptides |
| US4127534A (en) * | 1977-06-16 | 1978-11-28 | Coy David Howard | Novel tripeptides, intermediates therefor and pharmaceutical compositions and methods employing said tripeptides |
-
1981
- 1981-01-26 US US06/227,127 patent/US4340592A/en not_active Expired - Lifetime
- 1981-03-03 GB GB8106648A patent/GB2071670B/en not_active Expired
- 1981-03-04 DE DE3108079A patent/DE3108079C2/de not_active Expired
- 1981-03-04 FR FR8104278A patent/FR2477843A1/fr active Granted
- 1981-03-09 CH CH160081A patent/CH646874A5/de not_active IP Right Cessation
- 1981-03-11 NL NL8101182A patent/NL190951C/xx not_active IP Right Cessation
- 1981-03-12 SE SE8101585A patent/SE454746B/sv not_active IP Right Cessation
- 1981-03-13 AU AU68338/81A patent/AU543401B2/en not_active Ceased
- 1981-03-13 AT AT0117581A patent/AT372281B/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NL190951C (nl) | 1994-11-16 |
| NL8101182A (nl) | 1981-10-01 |
| AU6833881A (en) | 1981-09-17 |
| ATA117581A (de) | 1983-02-15 |
| SE454746B (sv) | 1988-05-30 |
| FR2477843B1 (enExample) | 1985-03-22 |
| AU543401B2 (en) | 1985-04-18 |
| DE3108079A1 (de) | 1982-01-21 |
| US4340592A (en) | 1982-07-20 |
| FR2477843A1 (fr) | 1981-09-18 |
| GB2071670B (en) | 1983-07-13 |
| AT372281B (de) | 1983-09-26 |
| NL190951B (nl) | 1994-06-16 |
| DE3108079C2 (de) | 1986-01-16 |
| SE8101585L (sv) | 1981-09-15 |
| GB2071670A (en) | 1981-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH646874A5 (de) | Naehrloesung. | |
| DE68905387T2 (de) | Aminosäure-Nahrungsmittelzusammensetzungen. | |
| DE2556100C2 (enExample) | ||
| DE69332433T2 (de) | Verbesserte aminosaureloesungen zur behandlung bei peritonealer dialyse | |
| DE60212693T2 (de) | Formulierung von aminosäuren und riboflavin zur verringerung der toxischen effekte der zytotoxischen chemotherapie | |
| DE69127087T2 (de) | Wachstumsfaktor und glutamin enthaltendes produkt und verwendung des wachstumsfaktors zur behandlung der darmschleimhaut | |
| DE3302008A1 (de) | Elementare diaet | |
| DE19530865A1 (de) | Wirkstoff sowie Mittel zur parenteralen Ernährung | |
| EP2734217B1 (de) | Produkt zur parenteralen ernährung von adipösen intensivpatienten | |
| DE2921312A1 (de) | Pharmazeutisches mittel und dessen verwendung bei einer vollstaendig parenteralen ernaehrung | |
| DE69331465T2 (de) | Intravenöse lösung, die den protein - und wasserverlust im körper reduziert | |
| DE4116004C2 (de) | Nährstoffzubereitung | |
| DE69220821T2 (de) | Verfahren zur Sicherstellung eines angemessenen intrazellulären Glutathionspiegels im Gewebe | |
| CH650678A5 (de) | Pharmazeutisches mittel aus human-insulin und human-proinsulin. | |
| DE2335215A1 (de) | Arzneimittel zur foerderung der proteinsynthese und zur unterdrueckung der harnstoffbildung | |
| DE2750159C3 (de) | Infusionslösung zur Behandlung von hepatischer Encephalopathie und ein Verfahren zu deren Herstellung | |
| DE69430416T3 (de) | Zusammensetzungen aus Aminosäure zur Behandlung von Infektionen | |
| DE3781268T2 (de) | Verwendung von wachstumshormonen zur stickstoffzurueckhaltung bei hypokalorischen bedingungen. | |
| DE2944341C2 (enExample) | ||
| DE3943424A1 (de) | Infusions- und injektionsloesung zur intravenoesen verabreichung | |
| DE2531299C2 (enExample) | ||
| DE2516027A1 (de) | Arzneimittel zur foerderung der proteinsynthese und zur konservierung des stickstoffs im koerper | |
| DE2740953A1 (de) | Verwendung von prostaglandinen zur senkung des blutzuckerspiegels | |
| DE2642768C2 (enExample) | ||
| DE69533742T2 (de) | Verwendung von Prolin und/oder Derivaten als Mittel gegen Hepatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUE | Assignment |
Owner name: MONTEFIORE HOSPITAL ASSOCIATION OF WESTERN PENNSYL |
|
| PL | Patent ceased |